Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.

The M1/M2 spectrum and plasticity of malignant pleural effusion-macrophage in advanced lung cancer

Open access

Abstract

Background: Malignant pleural effusion (MPE)-macrophage (Mφ) of lung cancer patients within unique M1/M2 spectrum showed plasticity in M1–M2 transition. The M1/M2 features of MPE-Mφ and their significance to patient outcomes need to be clarified; furthermore, whether M1-repolarization could benefit treatment remains unclear. Methods: Total 147 stage-IV lung adenocarcinoma patients undergoing MPE drainage were enrolled for profiling and validation of their M1/M2 spectrum. In addition, the MPE-Mφ signature on overall patient survival was analyzed. The impact of the M1-polarization strategy of patient-derived MPE-Mφ on anti-cancer activity was examined. Results: We found that MPE-Mφ expressed both traditional M1 (HLA-DRA) and M2 (CD163) markers and showed a wide range of M1/M2 spectrum. Most of the MPE-Mφ displayed diverse PD-L1 expression patterns, while the low PD-L1 expression group was correlated with higher levels of IL-10. Among these markers, we identified a novel two-gene MPE-Mφ signature, IL-1β and TGF-β1, representing the M1/M2 tendency, which showed a strong predictive power in patient outcomes in our MPE-Mφ patient cohort (N = 60, p = 0.013) and The Cancer Genome Atlas Lung Adenocarcinoma dataset (N = 478, p < 0.0001). Significantly, β-glucan worked synergistically with IFN-γ to reverse the risk signature by repolarizing the MPE-Mφ toward the M1 pattern, enhancing anti-cancer activity. Conclusions: We identified MPE-Mφ on the M1/M2 spectrum and plasticity and described a two-gene M1/M2 signature that could predict the outcome of late-stage lung cancer patients. In addition, we found that “re-education” of these MPE-Mφ toward anti-cancer M1 macrophages using clinically applicable strategies may overcome tumor immune escape and benefit anti-cancer therapies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s00262-020-02781-8

Cites

44 of 44 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 M1 and M2 markers are heterogeneously expressed in malignant pleural effusion-macrophages (MPE-Mφ) of advanced lung cancer patients. a MPE-Mφ with the common macrophage marker CD68 were double-positive for the expression of M1 (HLA-DR) and M2 (CD163) markers. MPE-Mφ isolated using anti-CD14 microbeads were characterized by flow cytometry with CD14, CD68, HLA-DR, and CD163 staining. Gating was based on isotype control staining. b The coexpression of M1 (HLA-DR) and M2 markers (CD163) by MPE-Mφ from 16 MPE samples was further evaluated by flow cytometry. One point indicates 1 MPE-Mφ case. c Heatmap of M1, M2 and common macrophage marker gene expression for 60 MPE-Mφ and for reference M1 and M2 macrophages (NCBI GEO series GSE5099). The arrangement of the 60 MPE-Mφ subjects was based on survival days, and programmed death-ligand 1 (PD-L1) expression levels for patients are also shown under the survival days for the indicated patients. Sample numbers of MPE-Mφ (N = 60) or triplicates of reference macrophages are listed in the columns. Gene expression levels are illustrated in a color gradient; red/yellow indicates high expression, while blue indicates low expression, as shown in the right panel. The names of the genes in each cluster can be seen in the left panel. d The M1/M2 gene expression distribution for MPE-Mφ and reference M1 and M2 macrophages (GEO database, GSE5099). As described in “Materials and methods”, the sum expression for six M1 genes (x-axis, M1) and five M2 genes (y-axis, M2) was plotted in the figure. Black closed circles indicate the 60 MPE-Mφ samples, individually; blue closed triangles indicate the triplicate GSE5099 M1 macrophages; red closed triangles indicate the triplicate GSE5099 M2 macrophages. e The correlation between IL-10 and PD-L1 was studied by constructing a scatterplot with a linear regression. IL-10 gene expression negatively correlated with PD-L1 was selected from Supplementary Fig. 2 and a scatterplot with PD-L1 was generated using the R package ggpubr [44] and ggplot2 [45]. The correlation (R) and p value are shown in the figure. One dot indicates an individual subject (N = 59, no. 18 listed in c was ruled out because of undetectable PD-L1 expression). The red dotted line (PD-L1 = − 4) separates the MPE-Mφ samples into PD-L1 high (N = 37) and low populations (N = 22). f The gene expression of PD-L1 and IL-10 in PD-L1 high and low populations. The PD-L1 gene expression levels of the MPE-Mφ subjects were divided into PD-L1 high and low populations as shown in e. H, PD-L1 high population (N = 37); L, PD-L1 low population (N = 22). Data were expressed as the means ± SEM and compared using an unpaired t test; **p < 0.01, ****p < 0.0001. c–f Expression of MPE-Mφ genes was calculated and normalized as described in “Materials and methods”. g–h Kaplan–Meier estimates of NSCLC patient survival according to the indicated M1 (IL-1β) and M2 (TGF-β1) gene signature of their MPE-Mφ. g Kaplan–Meier curves of the overall survival (OS) for NSCLC according to the indicated M1 (IL-1β) and M2 (TGF-β1) gene signature of their MPE-Mφ. N = 60; log-rank test, p = 0.013. h Kaplan–Meier curves of OS for the Cancer Genome Atlas Lung Adenocarcinoma (TCGA-LUAD) data stratified by M1 (IL-1β) and M2 (TGF-β1) gene expression. N = 478; log-rank test, p < 0.0001
Fig. 1 M1 and M2 markers are heterogeneously expressed in malignant pleural effusion-macrophages (MPE-Mφ) of advanced lung cancer patients. a MPE-Mφ with the common macrophage marker CD68 were double-positive for the expression of M1 (HLA-DR) and M2 (CD163) markers. MPE-Mφ isolated using anti-CD14 microbeads were characterized by flow cytometry with CD14, CD68, HLA-DR, and CD163 staining. Gating was based on isotype control staining. b The coexpression of M1 (HLA-DR) and M2 markers (CD163) by MPE-Mφ from 16 MPE samples was further evaluated by flow cytometry. One point indicates 1 MPE-Mφ case. c Heatmap of M1, M2 and common macrophage marker gene expression for 60 MPE-Mφ and for reference M1 and M2 macrophages (NCBI GEO series GSE5099). The arrangement of the 60 MPE-Mφ subjects was based on survival days, and programmed death-ligand 1 (PD-L1) expression levels for patients are also shown under the survival days for the indicated patients. Sample numbers of MPE-Mφ (N = 60) or triplicates of reference macrophages are listed in the columns. Gene expression levels are illustrated in a color gradient; red/yellow indicates high expression, while blue indicates low expression, as shown in the right panel. The names of the genes in each cluster can be seen in the left panel. d The M1/M2 gene expression distribution for MPE-Mφ and reference M1 and M2 macrophages (GEO database, GSE5099). As described in “Materials and methods”, the sum expression for six M1 genes (x-axis, M1) and five M2 genes (y-axis, M2) was plotted in the figure. Black closed circles indicate the 60 MPE-Mφ samples, individually; blue closed triangles indicate the triplicate GSE5099 M1 macrophages; red closed triangles indicate the triplicate GSE5099 M2 macrophages. e The correlation between IL-10 and PD-L1 was studied by constructing a scatterplot with a linear regression. IL-10 gene expression negatively correlated with PD-L1 was selected from Supplementary Fig. 2 and a scatterplot with PD-L1 was generated using the R package ggpubr [44] and ggplot2 [45]. The correlation (R) and p value are shown in the figure. One dot indicates an individual subject (N = 59, no. 18 listed in c was ruled out because of undetectable PD-L1 expression). The red dotted line (PD-L1 = − 4) separates the MPE-Mφ samples into PD-L1 high (N = 37) and low populations (N = 22). f The gene expression of PD-L1 and IL-10 in PD-L1 high and low populations. The PD-L1 gene expression levels of the MPE-Mφ subjects were divided into PD-L1 high and low populations as shown in e. H, PD-L1 high population (N = 37); L, PD-L1 low population (N = 22). Data were expressed as the means ± SEM and compared using an unpaired t test; **p < 0.01, ****p < 0.0001. c–f Expression of MPE-Mφ genes was calculated and normalized as described in “Materials and methods”. g–h Kaplan–Meier estimates of NSCLC patient survival according to the indicated M1 (IL-1β) and M2 (TGF-β1) gene signature of their MPE-Mφ. g Kaplan–Meier curves of the overall survival (OS) for NSCLC according to the indicated M1 (IL-1β) and M2 (TGF-β1) gene signature of their MPE-Mφ. N = 60; log-rank test, p = 0.013. h Kaplan–Meier curves of OS for the Cancer Genome Atlas Lung Adenocarcinoma (TCGA-LUAD) data stratified by M1 (IL-1β) and M2 (TGF-β1) gene expression. N = 478; log-rank test, p < 0.0001CC BY · PubMed Central
Fig. 2 M1 and M2 marker expression of MPE-Mφ was maintained with CLS1 cell-derived conditioned medium (CLS1 CM). a M1 and M2 marker expression of MPE-Mφ decreased on day 3. Validation of the expression of M1 (HLA-DR) and M2 markers (CD163) by MPE-Mφ on day 0 and day 3 by flow cytometry with 16 MPE samples. Day 0 is shown as D0, while day 3 is shown as D3 in the figure. D3 groups of MPE-Mφ were maintained in RPMI medium with 10% fetal bovine serum (FBS) for 3 days. Data shown as the means ± SEM and compared using a paired t test; **p < 0.01; ****p < 0.0001. One point indicates 1 MPE-Mφ case. N = 16. b MPE-Mφ were cocultured with increasing concentrations (10–100%) of CLS1 cell-derived conditioned medium (CLS1 CM) to maintain the double-positive M1 and M2 marker signals until day 3. Day 0 is shown as D0, while day 3 is shown as D3 in the figure. Blue words in the figures indicate the number of live macrophages. c Determination of the viability (%) of MPE-Mφ after coculturing with CLS1 CM for 3 days. Data are presented as the means ± SEM and compared using a paired t test. N = 11. d Representation of M2 (M1−M2+ and M1+M2+, blue line) and M1 (M1+M2−, red line) expression patterns with CLS1 CM (10%, 25%, 50% and 75%) among 11 MPE-Mφ samples. e Evaluation of M2 (blue bar) and M1 (red bar) expression % among 11 MPE-Mφ samples cultured with CM (10%, 25%, 50% and 75%). Data are expressed as the means ± SEM and compared using a paired t test; *p < 0.05; **p < 0.01; ***p < 0.001. A * above the bar indicates that a comparison between the indicated group and the non-group. b–e The non-group indicates MPE-Mφ that were cultured in RPMI medium with 10% FBS, and all other groups were cultured in the indicated medium with 10% FBS. f Expression of M1 (HLA-DR) and M2 (CD163) markers with different cytokine stimulation was detected by flow cytometry at day 3. All groups, unless specifically mentioned, were cultured in control medium (RPMI medium with 10% FBS). All cytokines in this study were used at a concentration of 100 ng/ml. Day 0 is shown as D0, while day 3 is shown as D3 in the figure. Blue words in the figures indicate the number of live macrophages (left panel). Flow cytometry was used to identify the M2+ populations among 6 MPE-Mφ samples with different treatments. One blue circle indicates one MPE-Mφ sample. Data shown as the means ± SEM and compared using a paired t test; *p < 0.05, N = 6 (right panel). g Determination of the % of M2+ MPE-Mφ after culturing with CLS1 CM in the presence of anti-IL-10 neutralizing antibody (left panel). The 75% CLS1 CM supplemented with 10% FBS was preincubated with IL-10 neutralizing antibody (NAb) or isotype-matched antibody (mIgG2b) for 1 h and then added to MPE-Mφ for 2 days. M1 (HLA-DR) and M2 (CD163) markers were validated by flow cytometry. The concentration of isotype-matched antibody (mIgG2b) and IL-10 NAb was 10 μg/ml. Blue words in the figures indicate the number of live macrophages. Case 1 and case 2 were two independent MPE-Mφ subjects (left panel). Flow cytometry was used to identify the M2+ populations among 7 MPE-Mφ samples with different treatments as described in the left panel. One blue circle indicates one MPE-Mφ sample. Data shown as the means ± SEM and compared using a paired t test; *p < 0.05, N = 7 (right panel)
Fig. 2 M1 and M2 marker expression of MPE-Mφ was maintained with CLS1 cell-derived conditioned medium (CLS1 CM). a M1 and M2 marker expression of MPE-Mφ decreased on day 3. Validation of the expression of M1 (HLA-DR) and M2 markers (CD163) by MPE-Mφ on day 0 and day 3 by flow cytometry with 16 MPE samples. Day 0 is shown as D0, while day 3 is shown as D3 in the figure. D3 groups of MPE-Mφ were maintained in RPMI medium with 10% fetal bovine serum (FBS) for 3 days. Data shown as the means ± SEM and compared using a paired t test; **p < 0.01; ****p < 0.0001. One point indicates 1 MPE-Mφ case. N = 16. b MPE-Mφ were cocultured with increasing concentrations (10–100%) of CLS1 cell-derived conditioned medium (CLS1 CM) to maintain the double-positive M1 and M2 marker signals until day 3. Day 0 is shown as D0, while day 3 is shown as D3 in the figure. Blue words in the figures indicate the number of live macrophages. c Determination of the viability (%) of MPE-Mφ after coculturing with CLS1 CM for 3 days. Data are presented as the means ± SEM and compared using a paired t test. N = 11. d Representation of M2 (M1−M2+ and M1+M2+, blue line) and M1 (M1+M2−, red line) expression patterns with CLS1 CM (10%, 25%, 50% and 75%) among 11 MPE-Mφ samples. e Evaluation of M2 (blue bar) and M1 (red bar) expression % among 11 MPE-Mφ samples cultured with CM (10%, 25%, 50% and 75%). Data are expressed as the means ± SEM and compared using a paired t test; *p < 0.05; **p < 0.01; ***p < 0.001. A * above the bar indicates that a comparison between the indicated group and the non-group. b–e The non-group indicates MPE-Mφ that were cultured in RPMI medium with 10% FBS, and all other groups were cultured in the indicated medium with 10% FBS. f Expression of M1 (HLA-DR) and M2 (CD163) markers with different cytokine stimulation was detected by flow cytometry at day 3. All groups, unless specifically mentioned, were cultured in control medium (RPMI medium with 10% FBS). All cytokines in this study were used at a concentration of 100 ng/ml. Day 0 is shown as D0, while day 3 is shown as D3 in the figure. Blue words in the figures indicate the number of live macrophages (left panel). Flow cytometry was used to identify the M2+ populations among 6 MPE-Mφ samples with different treatments. One blue circle indicates one MPE-Mφ sample. Data shown as the means ± SEM and compared using a paired t test; *p < 0.05, N = 6 (right panel). g Determination of the % of M2+ MPE-Mφ after culturing with CLS1 CM in the presence of anti-IL-10 neutralizing antibody (left panel). The 75% CLS1 CM supplemented with 10% FBS was preincubated with IL-10 neutralizing antibody (NAb) or isotype-matched antibody (mIgG2b) for 1 h and then added to MPE-Mφ for 2 days. M1 (HLA-DR) and M2 (CD163) markers were validated by flow cytometry. The concentration of isotype-matched antibody (mIgG2b) and IL-10 NAb was 10 μg/ml. Blue words in the figures indicate the number of live macrophages. Case 1 and case 2 were two independent MPE-Mφ subjects (left panel). Flow cytometry was used to identify the M2+ populations among 7 MPE-Mφ samples with different treatments as described in the left panel. One blue circle indicates one MPE-Mφ sample. Data shown as the means ± SEM and compared using a paired t test; *p < 0.05, N = 7 (right panel)CC BY · PubMed Central
Fig. 3 The combination of IFN-γ and β-glucan repolarized MPE-Mφ from M2 to M1 Mφ. a Expression of M1 (HLA-DR) and M2 (CD163) markers with different treatments, as indicated in the figure, was determined by flow cytometry. All groups were cultured in 75% CLS1 CM with 10% FBS until day 3. The concentration of β-glucan was 0.3 μg/ml. Blue words in the figures indicate the number of live macrophages. b Flow cytometry was used to identify M2 (M1−M2+, left panel) and M1 (M1+M2−, right panel) macrophages among 10 MPE-Mφ samples with different treatments. Data are expressed as the means ± SEM and compared using a paired t test; *p < 0.05; **p < 0.01. A * above the bar indicates that a comparison between the indicated group and the DMSO group. All groups were cultured in 75% CLS1 CM with 10% FBS until day 3. The concentrations of β-glucan and IFN-γ were 0.3 μg/ml and 12.5 ng/ml, respectively. a, b DMSO was the vehicle control for β-glucan
Fig. 3 The combination of IFN-γ and β-glucan repolarized MPE-Mφ from M2 to M1 Mφ. a Expression of M1 (HLA-DR) and M2 (CD163) markers with different treatments, as indicated in the figure, was determined by flow cytometry. All groups were cultured in 75% CLS1 CM with 10% FBS until day 3. The concentration of β-glucan was 0.3 μg/ml. Blue words in the figures indicate the number of live macrophages. b Flow cytometry was used to identify M2 (M1−M2+, left panel) and M1 (M1+M2−, right panel) macrophages among 10 MPE-Mφ samples with different treatments. Data are expressed as the means ± SEM and compared using a paired t test; *p < 0.05; **p < 0.01. A * above the bar indicates that a comparison between the indicated group and the DMSO group. All groups were cultured in 75% CLS1 CM with 10% FBS until day 3. The concentrations of β-glucan and IFN-γ were 0.3 μg/ml and 12.5 ng/ml, respectively. a, b DMSO was the vehicle control for β-glucanCC BY · PubMed Central
Fig. 4 Combination of IFN-γ and β-glucan repolarized MPE-Mφ toward the indicated M1 (IL-1β and HLA-DRA) and M2 (TGF-β1 and CD163) gene signatures and inhibited lung cancer cell proliferation. a Validation of M1 (IL-1β/HLA-DRA) and M2 (TGF-β1/CD163) gene expression after stimulation with the indicated treatments. MPE-Mφ were stimulated with the indicated treatment as described under the bar. Total RNA was harvested at 18 h post-stimulation for reverse-transcription into complementary DNA (cDNA). Gene expression levels were determined by real-time PCR and normalized to TATA-Box Binding Protein (TBP). Fold changes in gene expression on the y-axis were calculated based on the expression of the same gene in the DMSO-treated group. Data shown as the means ± SEM and compared using a paired t test; **p < 0.01; ***p < 0.001; N = 5. A * above the bar indicates a comparison between the indicated group and the DMSO group. The concentrations of β-glucan and IFN-γ were 0.3 μg/ml and 3.125 ng/ml, respectively. All groups were cultured in 75% CLS1 CM with 10% FBS. b Validation of the anti-proliferative effect of coculturing with CM derived from THP-1-derived M1 macrophages (positive control, left panel) and CM with the indicated treatments (right panel). Anti-tumor effects are presented as the percentage of control medium (Ctrl. medium) (left panel) and DMSO group (right panel). Data are expressed as the means ± SEM and were compared using the Mann–Whitney U test; *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001, N = 3. Ctrl. Medium indicates RPMI medium supplemented with 10% FBS. The concentration of β-glucan was 0.3 μg/ml and IFN-γ was 3.125 ng/ml, 6.25 ng/ml, or 12.5 ng/ml. a, b DMSO was the vehicle control for β-glucan. c Validation of the anti-proliferative effect contributed by IFN-γ/β-glucan-treated MPE-Mφ. A549 cells were stimulated with IFN-γ (100 ng/ml), TNF-α (100 ng/ml) or both cytokines for 3 days. Inhibition of A549 proliferation is shown as percentages of inhibition over control medium (all marks were -) (N = 3, left panel). CM from IFN-γ/β-glucan-treated MPE-Mφ was preincubated with IFN-γ, TNF-α or both neutralizing antibodies (NAb) (10 μg/ml) for 1 h and then added to A549 cells. Inhibition of A549 proliferation is shown as percentages of inhibition over control medium (all marks were -). One circle indicates 1 MPE-Mφ case (N = 8, right panel). Data are expressed as the means ± SEM and were compared using the Mann–Whitney U test; *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001. Control medium indicates RPMI medium supplemented with 10% FBS. The concentration of β-glucan was 0.3 μg/ml and IFN-γ was 12.5 ng/ml
Fig. 4 Combination of IFN-γ and β-glucan repolarized MPE-Mφ toward the indicated M1 (IL-1β and HLA-DRA) and M2 (TGF-β1 and CD163) gene signatures and inhibited lung cancer cell proliferation. a Validation of M1 (IL-1β/HLA-DRA) and M2 (TGF-β1/CD163) gene expression after stimulation with the indicated treatments. MPE-Mφ were stimulated with the indicated treatment as described under the bar. Total RNA was harvested at 18 h post-stimulation for reverse-transcription into complementary DNA (cDNA). Gene expression levels were determined by real-time PCR and normalized to TATA-Box Binding Protein (TBP). Fold changes in gene expression on the y-axis were calculated based on the expression of the same gene in the DMSO-treated group. Data shown as the means ± SEM and compared using a paired t test; **p < 0.01; ***p < 0.001; N = 5. A * above the bar indicates a comparison between the indicated group and the DMSO group. The concentrations of β-glucan and IFN-γ were 0.3 μg/ml and 3.125 ng/ml, respectively. All groups were cultured in 75% CLS1 CM with 10% FBS. b Validation of the anti-proliferative effect of coculturing with CM derived from THP-1-derived M1 macrophages (positive control, left panel) and CM with the indicated treatments (right panel). Anti-tumor effects are presented as the percentage of control medium (Ctrl. medium) (left panel) and DMSO group (right panel). Data are expressed as the means ± SEM and were compared using the Mann–Whitney U test; *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001, N = 3. Ctrl. Medium indicates RPMI medium supplemented with 10% FBS. The concentration of β-glucan was 0.3 μg/ml and IFN-γ was 3.125 ng/ml, 6.25 ng/ml, or 12.5 ng/ml. a, b DMSO was the vehicle control for β-glucan. c Validation of the anti-proliferative effect contributed by IFN-γ/β-glucan-treated MPE-Mφ. A549 cells were stimulated with IFN-γ (100 ng/ml), TNF-α (100 ng/ml) or both cytokines for 3 days. Inhibition of A549 proliferation is shown as percentages of inhibition over control medium (all marks were -) (N = 3, left panel). CM from IFN-γ/β-glucan-treated MPE-Mφ was preincubated with IFN-γ, TNF-α or both neutralizing antibodies (NAb) (10 μg/ml) for 1 h and then added to A549 cells. Inhibition of A549 proliferation is shown as percentages of inhibition over control medium (all marks were -). One circle indicates 1 MPE-Mφ case (N = 8, right panel). Data are expressed as the means ± SEM and were compared using the Mann–Whitney U test; *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001. Control medium indicates RPMI medium supplemented with 10% FBS. The concentration of β-glucan was 0.3 μg/ml and IFN-γ was 12.5 ng/mlCC BY · PubMed Central
Fig. 5 Characteristics of MPE-Mφ and IFN-γ/β-glucan-induced macrophage polarization. Figures represent M2–Mφ with M2 markers, M1–Mφ with M1 markers, and MPE-Mφ coexpressing M1 and M2 markers. IL-10 could maintain the MPE-Mφ phenotype. IFN-γ/β-glucan treatment re-educated MPE-Mφ to differentiate into tumor-killing macrophages with reduced M2 markers (TGF-β1 and CD163) and elevated IFN-γ and TNF-α production
Fig. 5 Characteristics of MPE-Mφ and IFN-γ/β-glucan-induced macrophage polarization. Figures represent M2–Mφ with M2 markers, M1–Mφ with M1 markers, and MPE-Mφ coexpressing M1 and M2 markers. IL-10 could maintain the MPE-Mφ phenotype. IFN-γ/β-glucan treatment re-educated MPE-Mφ to differentiate into tumor-killing macrophages with reduced M2 markers (TGF-β1 and CD163) and elevated IFN-γ and TNF-α productionCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 44 references

Cited by

See all 50

Metadata

Authors
Wu, M.-F., Lin, C.-A., Yuan, T.-H., Yeh, H.-Y., Su, S.-F., Guo, C.-L., Chang, G.-C., Li, K.-C., Ho, C.-C., & Chen, H.-W.
Affiliations
  • National Taiwan University (TW)
  • Soochow University (TW)
  • Institute of Physics, Academia Sinica (TW)
  • National Chung Hsing University (TW)
  • University of California, Los Angeles (US)
Corresponding author
  • Ho, Chao-Chi
  • Chen, Huei-Wen
Venue
Cancer Immunology, Immunotherapy
Published
2020-11-11
Volume
70
Issue
5
Pages
1435-1450
ISSN
  • 0340-7004 (ISSN-L)
  • 1432-0851
OpenAlex
W3105687100
Cited by
48
References
44
Citations by year
2026: 5 · 2025: 5 · 2024: 11 · 2023: 9 · 2022: 8 · 2021: 10
FWCI
2.36
Type
journal article
Language
en
Open access
Licence
Locations
  • Cancer Immunology Immunotherapy (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
  • Ministry of Science and Technology, Taiwan (107-2627-M-002-001-, 107-2314-B-002-244-MY3, 108-2321-B-038-003, 108-3114-Y-001-002)
  • Academia Sinica (AS-SUMMIT-108)
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Stress, Anesthesia, and Immune Response
Keywords
malignant pleural effusion, tumor-associated macrophages, macrophage polarization, macrophage plasticity, lung adenocarcinoma, stage IV lung cancer, IL-1β, TGF-β1, macrophage repolarization, β-glucan, interferon-gamma, PD-L1, IL-10, prognostic signature, tumor immune evasion, overall survival
MeSH terms
Cell Plasticity, Cell Differentiation, Cells, Cultured, Humans, Lung Neoplasms, Macrophages, Neoplasm Staging, Biomarkers, Tumor, Gene Expression Regulation, Neoplastic, Pleural Effusion, Malignant, Th1 Cells, Th2 Cells, Interleukin-1beta, Transforming Growth Factor beta1, Transcriptome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The M1/M2 spectrum and plasticity of malignant pleural effusion-macrophage in advanced lung cancer. https://app.cochat.ai/papers/10.1007/s00262-020-02781-8
The paper
Wu, M.-F., Lin, C.-A., Yuan, T.-H., Yeh, H.-Y., Su, S.-F., Guo, C.-L., Chang, G.-C., Li, K.-C., Ho, C.-C., & Chen, H.-W. (2021). The M1/M2 spectrum and plasticity of malignant pleural effusion-macrophage in advanced lung cancer. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-020-02781-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.